
May 8 (Reuters) - Viatris Inc VTRS.O:
VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF NOVEL FAST-ACTING MELOXICAM (MR-107A-02) FOR THE TREATMENT OF MODERATE-TO-SEVERE ACUTE PAIN
VIATRIS INC: ALL PRIMARY AND SECONDARY ENDPOINTS WERE MET IN BOTH PHASE 3 STUDIES
VIATRIS INC: TARGETING NEW DRUG APPLICATION SUBMISSION TO U.S. FDA BY END OF 2025